Research program

Alpine Immune Sciences Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Biotechnology, Pharmaceutical, Health, VRTX, ALPN, Investment, Research program, AbbVie, Research, Development, Alpine, Inflammation, Clinical trial, Vertex, Autoimmunity, Vertex Pharmaceuticals, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.
  • On April 10, 2024, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash.
  • The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024.
  • Cash Position and Runway: As of March 31, 2024, Alpine's cash and investments totaled $362.4 million compared to $368.2 million as of December 31, 2023.

Lennox-Gastaut Syndrome (LGS) Foundation Announces Exciting New Research Funded in Time for the 9th Annual Walk 'n' Wheel for LGS Research

Retrieved on: 
Dienstag, April 16, 2024
Research program, Weill Cornell Medical Center, Hope, Risk, Research, LGS, Lennox–Gastaut syndrome, Friends, DRS, Walking, SAN

SAN DIEGO, April 16, 2024 /PRNewswire/ -- On April 20, 2024, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 9th Annual Walk 'n' Wheel for LGS Research.

Key Points: 
  • SAN DIEGO, April 16, 2024 /PRNewswire/ -- On April 20, 2024, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 9th Annual Walk 'n' Wheel for LGS Research.
  • Lennox-Gastaut Syndrome (LGS) is a rare, severe, life-threatening epilepsy syndrome that develops in children and leads to lifelong disability.
  • A critical part of this Research Program is funding patient-led research by awarding Cure LGS 365 Research Grants.
  • The LGS Foundation recently funded an exciting new research study conducted by Drs.

Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

Retrieved on: 
Montag, März 18, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Research program, Administration, Congress, Development, WT, Lupus, Patient, Immunoglobulin A, Glomerular filtration rate, SLE, Inflammation, MD, UPCR, Neonatal Fc receptor, American College, Investment, Clinical trial, Society, EGFR, Nephrology, BAFF, Proteinuria, Immunoglobulin G, Autoimmunity, ALPN, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.
  • “2023 was a transformational year for Alpine, with initial IgA nephropathy (IgAN) data presented at the American Society of Nephrology Kidney Week 2023 suggesting a best-in-class profile for povetacicept, our next-generation dual BAFF/APRIL inhibitor.
  • In addition, povetacicept was well tolerated during subcutaneous administration, with no instances of IgG
  • Net Loss: Net loss for the year ended December 31, 2023, was $32.2 million compared to $57.8 million for the same period in 2022.

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Dienstag, November 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunoglobulin G, ASN, PMN, UPCR, Investment, Clinical trial, American Society of Nephrology, APRIL, Glomerular filtration rate, Administration, Patient, TACI, Inflammation, Immunoglobulin A, Neonatal Fc receptor, Lupus, Infection, Research program, BAFF, SLE, ALPN, Immunoglobulin M, MD, Development, EGFR, BCMA, Society, NIH Intramural Research Program, Autoimmunity, Proteinuria, AANEM, Pharmaceutical industry, Sewage treatment, Vaccine, Paint, IgA nephropathy, AbbVie, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
  • “Following our data presentation, we executed a follow-on equity offering of $150 million to bolster our balance sheet.
  • Cash Position and Runway: As of September 30, 2023, Alpine’s cash and investments totaled $227.2 million compared to $273.4 million as of December 31, 2022.
  • The respective increases of $0.8 million and $2.3 million were primarily attributable to increases in personnel and legal costs.

PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM

Retrieved on: 
Montag, Dezember 4, 2023
Obesity, Research program, FSE, PTPN1, The Company, Research, Diabetes, CSE, Vaccine

PreveCeutical has received direct interest in our diabetes & obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space.

Key Points: 
  • PreveCeutical has received direct interest in our diabetes & obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space.
  • To address the global rise of diabetes and obesity, and in furtherance of PreveCeutical's preventive health care focus, the Research Program builds on years of multi-disciplinary R&D in diabetes and obesity.
  • The rational design of tissue-targeted bioresponsive gene delivery systems (completed) will now be accompanied by gene- and protein-silencing in animal models of obesity and diabetes.
  • PreveCeutical has also approached multiple investment bankers and investors to provide the funding required to complete the preclinical studies.

BTQ and Hon Hai Research Institute Team Up To Help Pioneer Post-Quantum Cryptography Standards

Retrieved on: 
Mittwoch, November 29, 2023
Research, FRA, Electronics, NEO, Algorithm, NIH Intramural Research Program, Collaboration, Foxconn, Research program, Good, BTQ, PQC, Partnership, Molecular reference standards, NIST, Government, Property management, Pharmaceutical industry, Cryptocurrency

BTQ Technologies Corp. announces that its wholly owned subsidiary, BTQ AG, has entered into a Research and Collaboration Agreement with Hon Hai Research Institute.

Key Points: 
  • BTQ Technologies Corp. announces that its wholly owned subsidiary, BTQ AG, has entered into a Research and Collaboration Agreement with Hon Hai Research Institute.
  • In response to the call for PQC standard solicitation by the U.S. National Institute of Standards and Technology (NIST), BTQ and Hon Hai Research Institute's collaborative report was co-published in July 2023, demonstrating their combined expertise and commitment to advancing post-quantum cryptography standards.
  • The collaboration between BTQ and Hon Hai Research Institute began two years ago and the efforts in PQC led to the submission of a milestone report under the Research Program to the US National Institute of Standards and Technology (NIST) on June 1, 2023.
  • The contribution of Hon Hai Research Institute represents the forward-thinking direction in the field of post-quantum cryptography, which is in line with the trend of international academic research.

AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer

Retrieved on: 
Dienstag, Oktober 17, 2023
Health, National Science Advisory Board for Biosecurity, CSO, Protein engineering, R, Automotive Supplier Innovation Program, Big data, Protein, DSM (company), AMSilk, Advisory board, Research program, Management, Fine chemical

MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).

Key Points: 
  • MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).
  • Ulrich Scherbel, Chief Executive Officer of AMSilk, said: "Gudrun's skills and experience in designing proteins and accelerating time-to-market are of significant importance for AMSilk in the current scale-up phase."
  • Gudrun Vogtentanz, Chief Scientific Officer of AMSilk, added: "AMSilk's protein-based products unlock the secrets of spider silk to create engineerable structures and solutions.
  • I am excited to join AMSilk, and look forward to making a difference in sustainability while simultaneously delivering high-performance products."

AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer

Retrieved on: 
Dienstag, Oktober 17, 2023
Health, National Science Advisory Board for Biosecurity, CSO, Protein engineering, R, Automotive Supplier Innovation Program, Big data, Protein, DSM (company), AMSilk, Advisory board, Research program, Management, Fine chemical

MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).

Key Points: 
  • MUNICH, Oct. 17, 2023 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), the world's first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO).
  • Ulrich Scherbel, Chief Executive Officer of AMSilk, said: "Gudrun's skills and experience in designing proteins and accelerating time-to-market are of significant importance for AMSilk in the current scale-up phase."
  • Gudrun Vogtentanz, Chief Scientific Officer of AMSilk, added: "AMSilk's protein-based products unlock the secrets of spider silk to create engineerable structures and solutions.
  • I am excited to join AMSilk, and look forward to making a difference in sustainability while simultaneously delivering high-performance products."

Briefing on Capitol Hill Urges More Government Action and Investment in the Epilepsies

Retrieved on: 
Mittwoch, Mai 24, 2023
Epilepsy, Seizure, FY, Capitol Hill, Traumatic brain injury, Research program, SCN8A, Quality of life, Human, Tuberous sclerosis, Research, Child, Doctor of Philosophy, Government, Organization, TSC, Congress, National Hospital for Neurology and Neurosurgery, Children's National Hospital, Patient, Epilepsy Foundation, Tuberous sclerosis complex tumor suppressors, Fiscal year, Letter, Neurology, Pharmaceutical industry, SUDEP

WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.

Key Points: 
  • WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.
  • (R-NC-3) and Jim Costa (D-CA-21) spoke about their personal connections to epilepsy and the importance of the caucus.
  • "My son developed epilepsy when he was 14 and it took us months to get the right treatment for him," said Congressman Murphy.
  • The annual total healthcare burden for people living with the epilepsies and/or seizures is at least $54 billion.

Lennox-Gastaut Syndrome (LGS) Foundation Hosts 8th Annual Walk 'n' Wheel for LGS Research

Retrieved on: 
Montag, Mai 1, 2023
LGS, Education, Friends, Stanford University, Research program, DRS, Research, Deep brain stimulation, Brain, Lennox–Gastaut syndrome, DBS, Patient, SAN, Seizure, Disease, Epilepsy, Thermoplastic, Cure

SAN DIEGO, May 1, 2023 /PRNewswire/ -- On May 6, 2023, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 8th Annual Walk 'n' Wheel for LGS Research.

Key Points: 
  • SAN DIEGO, May 1, 2023 /PRNewswire/ -- On May 6, 2023, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 8th Annual Walk 'n' Wheel for LGS Research.
  • LGS is a rare, severe, life-threatening, epilepsy syndrome that develops in children and leads to lifelong disability.
  • The LGS Foundation is the only global organization dedicated to improving the lives of individuals and families impacted by LGS through advancing research, awareness, education, and family support.
  • A critical part of this Research Program is funding patient-led research by awarding Cure LGS 365 Research Grants.